MiMedx Group, Inc (NASDAQ:MDXG) Shares Sold by Farther Finance Advisors LLC

Farther Finance Advisors LLC reduced its position in MiMedx Group, Inc (NASDAQ:MDXG) by 26.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,592 shares of the company’s stock after selling 6,471 shares during the quarter. Farther Finance Advisors LLC’s holdings in MiMedx Group were worth $132,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. IMG Wealth Management Inc. acquired a new position in shares of MiMedx Group during the 4th quarter worth $28,000. Virtus Fund Advisers LLC purchased a new stake in shares of MiMedx Group during the fourth quarter worth about $35,000. Van ECK Associates Corp acquired a new position in MiMedx Group in the 4th quarter valued at $40,000. Tower Research Capital LLC TRC increased its stake in MiMedx Group by 77.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company’s stock valued at $63,000 after purchasing an additional 2,837 shares during the last quarter. Finally, AlphaQuest LLC purchased a new position in shares of MiMedx Group during the 4th quarter worth about $88,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Stock Down 1.5%

MiMedx Group stock opened at $5.81 on Friday. MiMedx Group, Inc has a 52 week low of $5.47 and a 52 week high of $10.14. The company has a current ratio of 4.70, a quick ratio of 4.13 and a debt-to-equity ratio of 0.09. The stock has a market cap of $858.14 million, a price-to-earnings ratio of 21.52 and a beta of 1.82. The company’s 50-day moving average price is $6.63 and its two-hundred day moving average price is $7.83.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, meeting the consensus estimate of $0.06. The business had revenue of $88.21 million during the quarter, compared to the consensus estimate of $86.32 million. MiMedx Group had a return on equity of 22.70% and a net margin of 11.40%. On average, analysts expect that MiMedx Group, Inc will post 0.3 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Joseph H. Capper acquired 200,000 shares of the company’s stock in a transaction dated Friday, May 2nd. The shares were bought at an average price of $6.34 per share, for a total transaction of $1,268,000.00. Following the acquisition, the chief executive officer now owns 529,530 shares in the company, valued at $3,357,220.20. This trade represents a 60.69% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.70% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 price objective on shares of MiMedx Group in a research note on Thursday, February 27th. Wall Street Zen upgraded shares of MiMedx Group from a “hold” rating to a “buy” rating in a report on Friday, June 6th.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.